US Bancorp’s Galmed Pharmaceuticals GLMD Stock Holding History

US Bancorp’s Portfolio GLMD Stock Details GLMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-10	Closed	-$9K	–	3678
2019 Q3	$9K	Hold	10	–	–	﹤0.01%	3076
2019 Q2	$14K	Sell	10 -3	-23%	-$3.87K	﹤0.01%	2995
2019 Q1	$19K	Hold	13	–	–	﹤0.01%	2872
2018 Q4	$15K	Buy	13 +11	+550%	+$19.2K	﹤0.01%	2915
2018 Q3	$5K	Hold	2	–	–	﹤0.01%	3309
2018 Q2	$4K	Buy	+2	New	+$2.9K	﹤0.01%	3368

Other funds holding GLMD

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Ibex Investors Denver, Colorado $152M AUM 19.17% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

RJA

Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return

PAWC

P.A.W. Capital Greenwich, Connecticut $88.2M AUM 25.13% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

RCG

Rock Creek Group Washington, District of Columbia $988M AUM 8.89% 1-Year Est. Return

US Bancorp's GLMD Position: Q4 2019 in Review

US Bancorp sold out of Galmed Pharmaceuticals (GLMD) in Q4 2019, closing a stake of 10 shares — an estimated $9K sold.

US Bancorp first reported a position in GLMD in Q2 2018 and held it in 6 quarters. The position peaked at $19K in Q1 2019. 31 funds tracked by Wall St. Rank hold GLMD as of Q4 2019.

US Bancorp reported no remaining Galmed Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
US Bancorp sold 10 Galmed Pharmaceuticals shares in Q4 2019, an estimated $9K.
US Bancorp first reported a position in Galmed Pharmaceuticals in Q2 2018 and held it in 6 quarters.
US Bancorp's Galmed Pharmaceuticals position peaked at $19K in Q1 2019.
31 funds tracked by Wall St. Rank held Galmed Pharmaceuticals as of Q4 2019.

Based on US Bancorp's 13F filing for Q4 2019, filed 4 Feb 2020.